(2-(cyclohexyloxy)pyridin-3-yl)boronic acid | 1621416-47-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2-(cyclohexyloxy)pyridin-3-yl)boronic acid
• 英文别名: 2-cyclohexyloxypyridine-3-boronic acid；2-cyclohexyloxypyridin-3-boronic acid；[2-(Cyclohexyloxy)pyridin-3-yl]boronic acid；(2-cyclohexyloxypyridin-3-yl)boronic acid
• CAS: 1621416-47-4
• 化学式: C₁₁H₁₆BNO₃
• 分子量: 221.064
• InChiKey: LCWJXCJSSIAQNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.47
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  62.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-(cyclohexyloxy)pyridin-3-yl)boronic acid 、 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine 生成 5-{4-[2-(cyclohexyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine
  参考文献：
  名称：

  FLAP MODULATORS

  摘要：

  本发明涉及公式(I)的化合物，或其形式，其中环A、R1、R2、R3、R3'、L、W和V的定义如本文所述，可用作FLAP调节剂。本发明还涉及包含公式(I)化合物的制药组合物。制备和使用公式(I)化合物的方法也属于本发明的范围。

  公开号：

  US20150259357A1

文献信息

• FLAP MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20140221311A1

  公开（公告）日：2014-08-07

  The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R 1 , R 2 , R 3 , R 3 ′, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention

  本发明涉及公式（I）的化合物，或其形式，其中环A、R1、R2、R3、R3'、L、W和V的定义如本文所述，可用作FLAP调节剂。本发明还涉及包含公式（I）化合物的药物组合物。制备和使用公式（I）化合物的方法也属于本发明的范围。
• 1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of Na V 1.7 inhibition
  作者：Alessandro A. Boezio、Kristin Andrews、Christiane Boezio、Margaret Chu-Moyer、Katrina W. Copeland、Erin F. DiMauro、Robert S. Foti、Robert T. Fremeau、Hua Gao、Stephanie Geuns-Meyer、Russell F. Graceffa、Hakan Gunaydin、Hongbing Huang、Daniel S. La、Joseph Ligutti、Bryan D. Moyer、Emily A. Peterson、Violeta Yu、Matthew M. Weiss

  DOI：10.1016/j.bmcl.2018.04.035

  日期：2018.6

  Recently, the identification of several classes of aryl sulfonamides and acyl sulfonamides that potently inhibit Na(v)1.7 and demonstrate high levels of selectivity over other Na-v isoforms have been reported. The fully ionizable nature of these inhibitors has been shown to be an important part of the pharmacophore for the observed potency and isoform selectivity. The requirement of this functionality, however, has presented challenges associated with optimization toward inhibitors with drug-like properties and minimal off-target activity. In an effort to obviate these challenges, we set out to develop an orally bioavailable, selective Na(v)1.7 inhibitor, lacking these acidic functional groups. Herein, we report the discovery of a novel series of inhibitors wherein a triazolesulfone has been designed to serve as a bioisostere for the acyl sulfonamide. This work culminated in the delivery of a potent series of inhibitors which demonstrated good levels of selectivity over Na v 1.5 and favorable pharmacokinetics in rodents. (C) 2018 Elsevier Ltd. All rights reserved.
• Flap modulators
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US09079866B2

  公开（公告）日：2015-07-14

  The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, R2, R3, R3′, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

  本发明涉及公式(I)的化合物或其形式，其中环A、R1、R2、R3、R3′、L、W和V的定义如本文所述，可用于FLAP调节剂。本发明还涉及包含公式(I)化合物的药物组成物。制备和使用公式(I)化合物的方法也属于本发明的范围。